Full Press Release Details
Applied DNA Announces Proposed Public
Common Stock and Warrants
STONY BROOK, N.Y. - December 19, 2018 - Applied
DNA Sciences, Inc. (Nasdaq: APDN) ("Applied DNA" or the "Company"), a leader in large-scale PCR-based DNA
manufacturing, announced today that it intends to offer for sale a combination of shares
of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The Company intends
to use the net proceeds from this offering for working capital, capital expenditures, business development and research and development
expenditures. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may
be completed, or as to the actual size or terms of the offering.
Maxim Group LLC is acting
as sole underwriter and book-running manager for the offering.
The securities described
above are being offered under the Company's shelf registration statement on Form S-3 (No. 333-218158), previously filed with
and declared effective by the U.S. Securities and Exchange Commission (SEC). The securities will be offered by means of a prospectus
supplement and accompanying prospectus, forming a part of the effective registration statement. The prospectus supplement and accompanying
prospectus related to the offering will be filed with the SEC and will be available on the website of the SEC at http://www.sec.gov.
Electronic copies of the prospectus supplement and accompanying prospectus also may be obtained from Maxim Group LLC, 405 Lexington
Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745. Before you invest, you should read the prospectus supplement and the accompanying
prospectus in the registration statement and other documents Applied DNA has filed or will file with the SEC for more complete
information about Applied DNA and the offering.
This press release shall
not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of
these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics,
personalized medicine and therapeutics.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow
us on Twitter and LinkedIn. Join our mailing list.
Forward Looking Statements
The statements made by Applied DNA in this press release may
be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA's future plans, projections, strategies and expectations, and are based on assumptions and involve a number
of risks and uncertainties, many of which are beyond the control of Applied DNA including the substantial doubt relating to the
Company's ability to continue as a going concern. Actual results could differ materially from those projected due to its
history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development,
future clinical data and analysis, including whether any of Applied DNA's product candidates will advance further in preclinical
research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign
regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S.
FDA or equivalent foreign regulatory agencies, shifting enforcement priorities of US federal
laws relating to cannabis, and various other factors detailed from time to time in Applied DNA's SEC reports and filings,
including our Annual Report on Form 10-K filed on December 18, 2018 and other reports we file with the SEC, which are available
at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information,
events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required
Investor contact: Sanjay M. Hurry, 212-838-3777, LHA
Investor Relations, shurry@lhai.com